NEOPLASM METASTASIS

This study is for people with endometrial cancer that has come back or spread to a few other spots. It tests a new drug called cadonilimab given together with chemotherapy and radiation. The goal is to see if this combination can shrink tumors and help people live longer without …

This early-stage study tests a new drug, LOXO-435, in people with advanced solid tumors, especially bladder cancer, that have a specific change in the FGFR3 gene. The goal is to find the safest dose and see if the drug can shrink tumors, either alone or with other cancer medicine…

This study tests whether adding a new drug (LY4064809) to standard hormone therapy and a CDK4/6 inhibitor can better control advanced HR+, HER2- breast cancer with a PIK3CA mutation. About 920 adults who have not had prior treatment for advanced disease will participate. The goal…

This early-phase study tests a new three-drug combination for people with head and neck cancer that has come back or spread. The goal is to find the safest dose and see if the treatment can shrink tumors or slow the disease. About 36 adults with this type of cancer will take part…

This early-stage study tests a new drug, LY4257496, that delivers radiation directly to cancer cells with a specific protein (GRPR). It is for adults with advanced breast, colorectal, prostate, or endometrial cancer that has spread. The goal is to find a safe dose and see if it s…

This study tests a new drug called LY4175408 in people with advanced lung, endometrial, or breast cancer that has spread. The drug is designed to target and kill cancer cells while sparing healthy ones. The goal is to check safety, how the drug moves through the body, and whether…

This study tests whether adding a new targeted drug (LY3537982) to standard treatments helps people with a specific genetic subtype of advanced non-small cell lung cancer (KRAS G12C mutation). About 1,264 participants will receive either the new drug combo or standard therapy. Th…

This study tests whether adding a new drug called vepugratinib to two standard cancer treatments (enfortumab vedotin and pembrolizumab) helps adults with advanced or spreading bladder cancer that has a specific FGFR3 gene change. About 450 participants will receive either the new…

This study tests a new drug, Sofetabart Mipitecan, for people with ovarian, fallopian tube, or peritoneal cancer. Part A includes those whose cancer no longer responds to platinum chemotherapy, and Part B includes those whose cancer still responds. The goal is to see if the new d…

This study aims to understand why prostate cancer grows and spreads differently in different people. Researchers will follow 3000 men with prostate cancer from Guadeloupe, Martinique, and Brittany, tracking their genetics, lifestyle, and health over time. The goal is to identify …

This study follows 800 adults with advanced HER2-positive, low, or ultralow breast cancer who are receiving the drug trastuzumab deruxtecan as part of their normal care. Researchers will track how long patients stay on the drug before switching treatments and how their quality of…